<DOC>
	<DOCNO>NCT00005945</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Giving one drug may kill cancer cell . It yet know combination chemotherapy regimen effective treat childhood acute lymphoblastic leukemia . PURPOSE : This randomized phase III trial compare different combination chemotherapy regimens see well work treat child acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Comparison Different Combination Chemotherapy Regimens Treating Children With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare event-free survival overall survival child standard-risk acute lymphoblastic leukemia treat escalating-dose IV methotrexate without leucovorin calcium versus oral methotrexate interim maintenance phase therapy . - Compare event-free survival overall survival patient receive treatment two delayed intensification phase versus one delay intensification phase . - Compare toxic effect oral versus escalating-dose intravenous methotrexate patient . - Determine prognostic significance rate disappearance peripheral lymphoblast lymphocyte first week treatment patient . - Determine prognostic significance trisomy chromosomes 4 , 5 , 10 , 17 early treatment response patient treat regimen . - Determine prognostic significance TEL-AML1 fusion transcript early treatment response patient treat regimen . - Determine minimal residual disease ( MRD ) polymerase chain reaction bone marrow cerebrospinal fluid various stage therapy patient . - Determine prognostic significance MRD various stage therapy patient . - Determine whether second delayed intensification therapy improve prognosis patient MRD end induction therapy . OUTLINE : This randomize , multicenter study . Patients without CNS disease diagnosis , achieve specify early marrow response profile M1 marrow status le 5 % blast bone marrow ( regardless proportion mature lymphocyte ) day 28 induction therapy , remain event free favorable bone marrow status cytogenetics day 21 28 consolidation therapy randomize one four treatment arm . Patients CNS disease diagnosis assign treatment arm II undergo cranial irradiation . Patients follow unfavorable bone marrow feature and/or unfavorable cytogenetic feature assign augmented treatment regimen day 21 induction chemotherapy begin consolidation chemotherapy : NOTE : All T-cell precursor patient 4 month past completion delay intensification phase therapy switch augmented regimen 3/8/2004 . These patient may switch augmented regimen . The protocol give specific instruction accord phase therapy patient actually . - Unfavorable marrow status : - M2 : 5-25 % blast bone marrow day 28 induction chemotherapy ( day 14 induction chemotherapy day 7 status M3 ) OR - M3 : More 25 % blast cell bone marrow , regardless proportion mature lymphocytes day 14 induction chemotherapy - Unfavorable cytogenetics : Must 1 following : - ( 9 ; 22 ) ( q34 ; q11 ) - ( 4 ; 11 ) ( q21 ; q23 ) - Balanced ( 1 ; 19 ) ( q23 ; p13 ) - Hypodiploidy le 45 chromosome - Other 11q23 translocation involve MLL Patients receive standard induction chemotherapy comprise cytarabine ( ARA-C ) intrathecally ( IT ) day 0 72 hour day 0 ; oral dexamethasone ( DM ) twice daily day 0-27 ; vincristine ( VCR ) IV day 0 , 7 , 14 , 21 ; pegaspargase ( PEG-ASP ) intramuscularly ( IM ) day 3-5 . Patients without CNS disease diagnosis receive methotrexate ( MTX ) IT day 7 28 . Patients CNS disease diagnosis receive MTX IT day 7 , 14 , 21 , 28 . Patients achieve M1 marrow status day 28 induction therapy favorable early bone marrow response cytogenetics proceed standard consolidation therapy blood count recover . Patients M3 bone marrow status day 28 induction therapy take protocol . All patient assign augmented treatment regimen . Beginning day 28 induction chemotherapy , patient receive standard consolidation chemotherapy comprise VCR IV day 0 oral mercaptopurine ( MP ) day 0-27 . Patients without CNS disease diagnosis receive MTX IT day 7 , 14 , 21 , 28 . Patients CNS disease diagnosis receive MTX IT day 7 cranial irradiation 5 day week 2 week . Patients testicular disease receive bilateral testicular radiotherapy 5 day week 1 week 3 consecutive day next week . NOTE : As 3/8/2004 , patient T-cell disease achieve M1 marrow status day 14 induction OR receive augment induction and/or consolidation ( regardless early marrow status ) receive cranial irradiation . - Arm I : Beginning day 28 consolidation chemotherapy , patient receive interim maintenance I chemotherapy comprise oral DM twice daily day 0-4 28-32 ; VCR IV day 0 28 ; oral MTX day 0 , 7 , 14 , 21 , 28 , 35 , 42 , 49 ; oral MP day 0-49 ; MTX IT day 28 . Beginning day 56 interim maintenance I chemotherapy , patient receive delay intensification chemotherapy comprise oral DM twice daily day 0-6 14-20 ; VCR IV doxorubicin ( DOX ) IV 15 minute 2 hour day 0 , 7 , 14 ; PEG-ASP IM day 3 ; cyclophosphamide ( CTX ) IV 20-30 minute day 28 ; oral thioguanine ( TG ) day 28-41 ; ARA-C IV subcutaneously ( SC ) daily day 28-31 35-38 ; MTX IT day 0 28 . Beginning day 56 delay intensification chemotherapy , patient receive interim maintenance II chemotherapy identical interim maintenance I chemotherapy except patient receive MTX IT day 0 28 . Beginning day 56 interim maintenance II chemotherapy , patient receive maintenance chemotherapy comprise oral DM twice daily day 0-4 , 28-32 , 56-60 ; VCR IV day 0 , 28 , 56 ; oral MP day 0-83 ; oral MTX day 7 , 14 , 21 , 28 , 35 , 42 , 49 , 56 , 63 , 70 , 77 ; MTX IT day 0 . - Arm II : Patients receive interim maintenance I chemotherapy , delayed intensification chemotherapy , interim maintenance II chemotherapy arm I . Beginning day 56 interim maintenance II chemotherapy , patient receive second course delay intensification chemotherapy follow maintenance chemotherapy arm I . - Arm III : Beginning day 28 consolidation chemotherapy , patient receive interim maintenance I chemotherapy comprise VCR IV ; escalate dos MTX IV day 0 , 10 , 20 , 30 , 40 ; MTX IT day 30 . Patients receive delay intensification chemotherapy arm I . Patients receive interim maintenance II chemotherapy interim maintenance I chemotherapy , IV MTX start 2/3 maximum tolerate dose ( MTD ) attain interim maintenance I chemotherapy . Patients receive maintenance chemotherapy arm I . - Arm IV : Patients receive interim maintenance I chemotherapy arm III , delayed intensification chemotherapy arm I , interim maintenance II chemotherapy arm III , delay intensification II chemotherapy arm II , maintenance chemotherapy arm I . - Augmented Treatment : Patients receive induction chemotherapy comprise daunorubicin IV continuously 48 hour begin later day 21 ; oral DM twice daily day 14-27 ; VCR IV day 14 21 . Patients without CNS disease diagnosis receive MTX IT day 21 35 . Patients CNS disease diagnosis receive MTX IT day 21 28 . NOTE : Patients T-cell disease re-start augment consolidation proceed per augment regimen . Beginning day 35 induction chemotherapy , patient receive consolidation therapy comprise CTX IV 20-30 minute day 0 28 ; oral MP day 0-13 28-41 ; ARA-C IV SC daily day 0-3 , 7-10 , 28-31 , 35-38 ; VCR IV day 14 , 21 , 42 , 49 ; PEG-ASP IM day 14 42 . Patients without CNS disease diagnosis receive MTX IT day 7 , 14 , 21 . Patients CNS disease diagnosis receive MTX IT day 7 cranial irradiation randomize treatment section . Patients testicular leukemia receive radiotherapy randomize treatment section . Beginning day 63 consolidation chemotherapy , patient receive interim maintenance I chemotherapy comprise VCR IV day 0 , 10 , 20 , 30 , 40 ; escalate dos MTX IV day 10 , 20 , 30 , 40 ; PEG-ASP IM day 1 21 ; MTX IT day 0 30 . Beginning day 56 interim maintenance I chemotherapy , patient receive delay intensification I chemotherapy comprise oral DM twice daily day 0-6 14-20 ; VCR IV day 0 , 7 , 14 , 42 , 49 ; DOX IV 15 minute 2 hour day 0 , 7 , 14 ; PEG-ASP IM day 3 42 ; CTX IV 20-30 minute day 28 ; oral TG day 28-41 ; ARA-C IV SC daily day 28-31 35-38 ; MTX IT day 0 28 . NOTE : Patients T-cell disease interim maintenance I chemotherapy escalate IV methotrexate continue phase proceed per augment regimen . If patient receive conventional interim maintenance chemotherapy oral methotrexate , stop restart interim maintenance per augment regimen . These patient receive cranial irradiation start day 28 delay intensification II chemotherapy . Beginning day 56 delayed intensification I chemotherapy , patient receive interim maintenance II chemotherapy interim maintenance I chemotherapy , IV MTX start 2/3 MTD attain interim maintenance I chemotherapy . NOTE : Patients T-cell disease delay intensification I chemotherapy proceed phase , addition 2 vincristine dos day 42 49 PEG-ASP day 42 . These patient proceed per augment regimen addition cranial irradiation start day 28 delay intensification II chemotherapy . NOTE : Patients T-cell disease within 4 month complete delayed intensification I chemotherapy receive interim maintenance II chemotherapy escalate IV methotrexate delay intensification II chemotherapy receive course interim maintenance chemotherapy delay intensification II chemotherapy accord augmented regimen . If patient receive interim maintenance II chemotherapy escalate IV methotrexate , receive delay intensification II chemotherapy accord augmented regimen . These patient also receive cranial irradiation start day 28 delay intensification II chemotherapy proceed maintenance therapy . Beginning day 56 interim maintenance II chemotherapy , patient receive delay intensification II chemotherapy delay intensification I chemotherapy . Beginning day 56 delay intensification II chemotherapy , patient receive maintenance chemotherapy comprise oral DM twice daily day 0-4 , 28-32 , 56-60 ; VCR IV day 0 , 28 , 56 ; oral MP day 0-83 ; oral MTX day 7 , 14 , 21 , 28 , 35 , 42 , 49 , 56 , 63 , 70 , 77 ; MTX IT day 0 . Patients follow every 4-8 week one year , every 3 month one year , every 6 month one year , annually thereafter . PROJECTED ACCRUAL : A total 2,037 randomized patient accrue study within 3.75 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis previously untreated Bcell precursor acute lymphoblastic leukemia More 25 % L1 L2 lymphoblasts No 25 % L3 lymphoblasts WBC &lt; 50,000/mm^3 No Tcell precursor acute lymphoblastic leukemia immunophenotyping Massive lymphadenopathy , massive splenomegaly , large mediastinal mass allow CNS testicular leukemia allow No patient find ( 8 ; 14 ) ( q24 ; q32 ) , ( 8 ; 22 ) ( q24 ; q11 ) , ( 2 ; 8 ) ( p11p12 ; q24 ) ( characteristic Burkitt 's lymphoma ) PATIENT CHARACTERISTICS : Age : 1 9 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Other : Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 72 hour since prior intrathecal cytarabine Endocrine therapy : At least 30 day since prior systemic corticosteroid give 48 hour Prior corticosteroid mediastinal mass cause superior mediastinal syndrome allow Prior concurrent inhale corticosteroid allow Radiotherapy : Prior radiotherapy mediastinal mass cause superior mediastinal syndrome allow No concurrent spinal radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L3 childhood acute lymphoblastic leukemia</keyword>
</DOC>